Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence

PURPOSE: To describe the lung function and clinical control of asthma in patients with N-ERD during three years of medical follow-up using GINA guidelines.

METHODS: We evaluated 75 N-ERD and 68 asthma patients (AG).

Clinical control, lung function, and asthma treatment were evaluated according to GINA-2014.

We compared all variables at baseline and one, two, and three years after treatment.

RESULTS: At baseline, the N-ERD group had better basal lung function (LF) than the AG group (p<0.01), and the AG group used higher doses of inhaled corticosteroids than the N-ERD group (52.4% vs 30.5%, p=0.01) and short-term oral corticosteroid (OCS) use (52.4% vs 30.5%, p<0.01).

Instead, N-ERD patients needed more use of leukotriene receptor antagonists (LTRA) (29.3% vs 5.9%, p<0.01).

This group had better clinical control than the AG group (62.1% vs 34.1%, p<0.01).

During the medical follow-up, the LF of the N-ERD group remained at normal values; however, these parameters improved in AG from one year (p<0.01).

Likewise, there was a diminished use of high doses of ICS (52.4% vs 33%, p<0.05) and short-term OCS (67.6% vs 20.6%, p<0.01) in asthma patients.

However, N-ERD patients still needed more use of LTRAs (p<0.02) during the study.

In this context, one-third of N-ERD patients had to use a combination of two drugs to maintain this control.

From the second year on, clinical control of asthma was similar in both groups (p>0.05).

CONCLUSION: According to GINA guidelines, only one-third of patients with N-ERD can gradually achieve adequate lung function and good asthma control with a high ICS dosage.

Only a very small portion of patients will require the continued use of a second medication as an LTRA to keep their asthma under control.